Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Esperion Therapeutics, Inc. develops and markets medical devices. The Company produces oral and small molecule therapies for the treatment of patients with elevated levels of low-density lipoprotein cholesterol and other cardio metabolic risk factors.
Website: esperion.com


  • Good financial results growth rate 200.0% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (33.4%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -7.6% (LTM)
  • Share price is 187.5% higher than minimum and 92.0% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (500.0x vs 30.0x)

Key Financials (Download financials)

Ticker: ESPR
Share price, USD:  (-1.4%)2.1
year average price 1.79  


year start price 1.36 2023-05-31

min close price 0.73 2023-10-26

max close price 3.24 2024-04-05

current price 2.10 2024-05-29
Common stocks: 169 258 564

Dividend Yield:  0.0%
Last revenue growth (y/y):  200.0%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  60.5%
Historical growth of EBITDA:  6.3%
EV / Sales: 2.1x
Margin (EBITDA LTM / Revenue): -13.9%

Target EV / EBITDA (hist percentile): 30.0x
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 355
Net Debt ($m): 125
EV (Enterprise Value): 480
EBITDA LTM (млн $): -32
Price to Book: -1.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2024-05-23zacks.com

Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk

2024-05-20globenewswire.com

Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia

2024-05-08Zacks Investment Research

Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues

2024-05-07Zacks Investment Research

Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates

2024-04-29GlobeNewsWire

Esperion to Participate in Upcoming May Investor Conferences

2024-04-01Schwab Network

Esperion Therapeutics (ESPR) CEO on Cholesterol Lowering Medications

2024-02-28Seeking Alpha

A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics

2024-02-28Zacks Investment Research

Esperion (ESPR) Q4 Earnings Top, Stock Up on Strong Revenues

2024-02-27Zacks Investment Research

Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue Estimates

2024-02-13Zacks Investment Research

Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ESPR ESPR ESPR ESPR ESPR ESPR ESPR
reportedCurrency USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-05-07 2024-02-27 2023-11-07 2023-08-01 2023-05-09 2023-02-21 2022-11-01
acceptedDate 2024-05-07 08:50:20 2024-02-27 09:19:19 2023-11-07 08:52:03 2023-08-01 08:51:20 2023-05-09 09:00:39 2023-02-21 09:25:07 2022-11-01 08:52:54
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 138M 32M 34M 26M 24M 19M 19M
costOfRevenue 10M 11M 13M 7M 12M 4M 7M
grossProfit 128M 21M 21M 19M 13M 15M 12M
grossProfitRatio 0.927 0.645 0.606 0.737 0.521 0.779 0.657
researchAndDevelopmentExpenses 13M 18M 15M 22M 31M 33M 29M
generalAndAdministrativeExpenses 0 30M 0 0 0 0 0
sellingAndMarketingExpenses 0 16M 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 42M 45M 33M 34M 30M 24M 25M
otherExpenses 10M 1M 13M 7M 1M 1M 0
operatingExpenses 65M 63M 62M 63M 61M 57M 54M
costAndExpenses 65M 75M 62M 63M 73M 61M 61M
interestIncome 0 900 000 1M 2M 0 0 0
interestExpense -14M 15M -15M -15M 14M 14M 14M
depreciationAndAmortization 41 000 6000.000 26 000 51 000 1M 1M 764 000
ebitda 72M -42M -28M -37M -47M -41M -41M
ebitdaratio 0.525 -1.314 -0.811 -1.437 -1.945 -2.187 -2.153
operatingIncome 72M -42M -28M -37M -49M -43M -42M
operatingIncomeRatio 0.525 -1.314 -0.811 -1.437 -1.998 -2.259 -2.193
totalOtherIncomeExpensesNet -11M -14M -14M -13M -13M -13M -13M
incomeBeforeTax 61M -56M -41M -50M -62M -55M -55M
incomeBeforeTaxRatio 0.443 -1.747 -1.214 -1.937 -2.537 -2.949 -2.904
incomeTaxExpense -41 000 -27M -26 000 -51 000 28M 13M 13M
netIncome 61M -56M -41M -50M -89M -68M -69M
netIncomeRatio 0.443 -1.747 -1.214 -1.937 -3.667 -3.638 -3.615
eps 0.360 -0.500 -0.370 -0.460 -1.140 -0.930 -1.010
epsdiluted 0.320 -0.500 -0.370 -0.460 -1.140 -0.930 -1.010
weightedAverageShsOut 169M 112M 112M 109M 78M 73M 68M
weightedAverageShsOutDil 190M 112M 112M 109M 78M 73M 68M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ESPR ESPR ESPR ESPR ESPR ESPR ESPR
reportedCurrency USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-05-07 2024-02-27 2023-11-07 2023-08-01 2023-05-09 2023-02-21 2022-11-01
acceptedDate 2024-05-07 08:50:20 2024-02-27 09:19:19 2023-11-07 08:52:03 2023-08-01 08:51:20 2023-05-09 09:00:39 2023-02-21 09:25:07 2022-11-01 08:52:54
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 227M 82M 115M 138M 145M 125M 159M
shortTermInvestments 0 0 0 0 17M 42M 30M
cashAndShortTermInvestments 227M 82M 115M 138M 162M 125M 189M
netReceivables 55M 48M 43M 41M 36M 34M 31M
inventory 73M 66M 51M 46M 39M 35M 30M
otherCurrentAssets 11M 5M 6M 4M 6M 10M 11M
totalCurrentAssets 366M 201M 218M 232M 251M 247M 262M
propertyPlantEquipmentNet 7M 5M 3M 2M 1M 1M 986 000
goodwill 0 0 0 0 0 0 0
intangibleAssets 56 000 56 000 56 000 56 000 56 000 56 000 56 000
goodwillAndIntangibleAssets 56 000 56 000 56 000 56 000 56 000 56 000 56 000
longTermInvestments 0 0 0 0 0 42M 0
taxAssets 0 0 0 0 0 0 0
otherNonCurrentAssets 0 -1.000 0 -3M 0 -42M 50M
totalNonCurrentAssets 7M 5M 3M 3M 1M 1M 51M
otherAssets 0 1.000 0 0 0 0 0
totalAssets 373M 206M 221M 235M 252M 248M 313M
accountPayables 28M 32M 26M 25M 17M 23M 19M
shortTermDebt 46M 36M 918 000 687 000 305 000 384 000 693 000
taxPayables 0 0 0 0 0 0 0
deferredRevenue 29M 25M 20M 16M 12M 4M 4M
otherCurrentLiabilities 61M 63M 91M 66M 66M 65M 59M
totalCurrentLiabilities 165M 156M 138M 107M 95M 92M 82M
longTermDebt 498M 502M 263M 262M 261M 261M 260M
deferredRevenueNonCurrent 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0
otherNonCurrentLiabilities 4M 3M 230M 237M 225M 219M 501M
totalNonCurrentLiabilities 503M 505M 494M 499M 486M 479M 525M
otherLiabilities 1.000 0 0 0 0 0 0
capitalLeaseObligations 4M 3M 3M 2M 1M 1M 740 000
totalLiabilities 667M 661M 631M 607M 581M 572M 607M
preferredStock 1.000 0 1.000 0 0 0 0
commonStock 188 000 118 000 112 000 101 000 87 000 75 000 72 000
retainedEarnings -1 488M -1 549M -1 493M -1 452M -1 402M -1 340M -1 285M
accumulatedOtherComprehensiveIncomeLoss 0.000 -0.000 0.000 0 -1000.000 -2000.000 -93 000
othertotalStockholdersEquity 1 194M 1 094M 1 083M 1 080M -86 000 -73 000 990M
totalStockholdersEquity -294M -455M -410M -372M -1 402M -1 340M -294M
totalEquity -294M -455M -410M -372M -1 402M -1 340M -294M
totalLiabilitiesAndStockholdersEquity 373M 206M 221M 235M -820M -768M 313M
minorityInterest 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 373M 206M 221M 235M -820M -768M 313M
totalInvestments 0 0 0 0 17M 84M 30M
totalDebt 549M 541M 264M 263M 261M 261M 260M
netDebt 322M 459M 149M 125M 116M 136M 101M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ESPR ESPR ESPR ESPR ESPR ESPR ESPR
reportedCurrency USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-05-07 2024-02-27 2023-11-07 2023-08-01 2023-05-09 2023-02-21 2022-11-01
acceptedDate 2024-05-07 08:50:20 2024-02-27 09:19:19 2023-11-07 08:52:03 2023-08-01 08:51:20 2023-05-09 09:00:39 2023-02-21 09:25:07 2022-11-01 08:52:54
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome 61M -56M -41M -50M -62M -55M -55M
depreciationAndAmortization 437 000 6000.000 26 000 51 000 81 000 92 000 105 000
deferredIncomeTax 0 -17M 0 -73 000 0 0 0
stockBasedCompensation 3M 3M 3M 3M 3M 4M 4M
changeInWorkingCapital -22M 4M 7M 10M -7M -2M -3M
accountsReceivables -6M -6M -2M -4M -3M -2M -4M
inventory -7M -14M -6M -6M -4M -6M -313 000
accountsPayables -3M 6M 2M 7M -6M 4M 6M
otherWorkingCapital -5M 19M 13M 13M 6M 1M -5M
otherNonCashItems 32M 30M 12M 12M 11M 11M 12M
netCashProvidedByOperatingActivities 54M -37M -19M -25M -54M -42M -43M
investmentsInPropertyPlantAndEquipment -73 000 0 0 0 0 0 0
acquisitionsNet 0 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 -42M 0
salesMaturitiesOfInvestments 0 0 0 18M 25M 30M 33M
otherInvestingActivites 0 -43M 0 0 0 0 0
netCashUsedForInvestingActivites -73 000 0 0 18M 25M -12M 33M
debtRepayment -6M -5M -4M -4M 0 0 0
commonStockIssued 96M 9M -52M 4M 53M 22M 49M
commonStockRepurchased 0 20 000 -20 000 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0
otherFinancingActivites -66 000 4M 52M 10000.000 -3M -52M -2M
netCashUsedProvidedByFinancingActivities 91M 4M -4M 809 000 49M -30M 46M
effectOfForexChangesOnCash 0 0 0 0 0 0 0
netChangeInCash 144M -33M -24M -6M 20M -85M 36M
cashAtEndOfPeriod 227M 82M 115M 138M 145M 125M 209M
cashAtBeginningOfPeriod 82M 115M 138M 145M 125M 209M 173M
operatingCashFlow 54M -37M -19M -25M -54M -42M -43M
capitalExpenditure -73 000 0 0 0 0 0 0
freeCashFlow 54M -37M -19M -25M -54M -42M -43M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Earning call transcript

2024 q1
2024-05-07 ET (fiscal 2024 q1)
2023 q4
2024-02-27 ET (fiscal 2023 q4)
2023 q3
2023-11-07 ET (fiscal 2023 q3)
2023 q2
2023-08-01 ET (fiscal 2023 q2)
2023 q1
2023-05-09 ET (fiscal 2023 q1)
2022 q4
2023-02-21 ET (fiscal 2022 q4)
2022 q3
2022-11-01 ET (fiscal 2022 q3)
2022 q2
2022-08-02 ET (fiscal 2022 q2)
2022 q1
2022-05-03 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-05-07 10:00 ET
Esperion Reports First Quarter 2024 Financial Results
2024-04-29 12:00 ET
Esperion to Participate in Upcoming May Investor Conferences
2024-04-23 12:00 ET
Esperion to Report First Quarter 2024 Financial Results on May 7
2024-04-07 18:45 ET
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
2024-04-01 12:00 ET
Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
2024-03-26 12:00 ET
Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
2024-03-25 20:00 ET
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
2024-03-22 22:26 ET
U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
2024-03-22 19:10 ET
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
2024-03-22 15:04 ET
CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events
2024-02-27 11:00 ET
Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-16 21:30 ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2024-02-13 13:00 ET
Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27
2024-02-01 19:00 ET
RFK, Esperion Therapeutics Announce 2024 Promotional Schedule
2024-01-23 21:00 ET
Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
2024-01-19 02:15 ET
Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock
2024-01-18 21:00 ET
Esperion Announces Proposed Public Offering of Common Stock
2024-01-03 12:00 ET
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation
2024-01-03 12:00 ET
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation
2023-12-18 13:00 ET
Esperion to Participate in 42nd Annual J.P. Morgan Healthcare Conference
2023-12-13 21:00 ET
U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet
2023-11-13 15:30 ET
Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023
2023-11-11 16:00 ET
Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023
2023-11-09 21:30 ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2023-11-07 11:00 ET
Esperion Reports Third Quarter 2023 Financial Results
2023-10-31 12:00 ET
Esperion to Participate in Jefferies London Healthcare Conference
2023-10-24 12:00 ET
Esperion to Report Third Quarter 2023 Financial Results on November 7
2023-09-12 14:15 ET
American College of Cardiology Program to Increase Cholesterol Screenings
2023-08-28 12:00 ET
Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference
2023-08-26 15:00 ET
Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023
2023-08-11 12:00 ET
Two CLEAR Outcomes Study Late-Breakers Accepted at European Society of Cardiology (ESC) Congress 2023
2023-08-08 20:15 ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2023-08-01 10:00 ET
Esperion Reports Second Quarter 2023 Financial Results
2023-07-24 12:00 ET
Esperion to Participate in BTIG Virtual Biotechnology Conference 2023
2023-07-17 10:00 ET
Esperion to Report Second Quarter 2023 Financial Results on August 1
2023-07-07 12:00 ET
Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023
2023-06-28 12:00 ET
Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet
2023-06-24 18:30 ET
Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions
2023-06-15 18:30 ET
Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023
2023-06-08 12:00 ET
Esperion to Present New Key Science at the American Diabetes Association’s 83rd Scientific Sessions 2023
2023-06-05 12:00 ET
Esperion to Present Additional Analyses from the Landmark CLEAR Outcomes Study at ENDO 2023
2023-06-01 12:00 ET
Esperion Announces Submission of Supplemental New Drug Applications to U.S. FDA for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet
2023-05-25 20:30 ET
Esperion Announces Adjournment of 2023 Annual Meeting of Stockholders
2023-05-24 12:00 ET
Esperion to Participate in Jefferies Healthcare Conference
2023-05-12 20:30 ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2023-05-09 11:00 ET
Esperion Reports First Quarter 2023 Financial Results
2023-05-04 12:30 ET
Esperion Retains Gibson Dunn to Secure $300 Million Payment From DSE; Will Announce First Quarter Financial Results Tuesday, May 9
2023-05-01 12:00 ET
Esperion to Participate in JMP Securities Life Sciences Conference
2023-04-27 12:00 ET
Esperion to Participate in Bank of America Securities 2023 Health Care Conference
2023-04-25 12:00 ET
Esperion to Report First Quarter 2023 Financial Results May 9, 2023
2023-04-19 12:42 ET
Esperion Announces Co-Promotion Agreement With Currax Pharmaceuticals LLC
2023-04-03 12:00 ET
Esperion to Participate in Needham 22nd Annual Virtual Healthcare Conference
2023-03-20 12:00 ET
Esperion Announces $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
2023-03-08 13:00 ET
International Lipid Expert Panel (ILEP) Recommends Use of Bempedoic Acid Ahead of PCSK9 Inhibitors in Managing Lipid Disorders and Cardiovascular Risk
2023-03-04 15:30 ET
Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prevention and Secondary Prevention Patients
2023-02-24 18:40 ET
Esperion Launches New Scientific Website
2023-02-23 13:00 ET
Esperion to Participate in the Cowen 43rd Annual Healthcare Conference
2023-02-22 13:00 ET
CLEAR Outcomes Company Update Call: Detailed Results Discussion
2023-02-21 12:00 ET
Esperion Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
2023-02-20 13:00 ET
Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23/WCC
2023-02-13 21:30 ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2023-02-07 13:00 ET
Esperion to Report Fourth Quarter and Full Year 2022 Financial Results February 21, 2023
2023-01-11 16:00 ET
RFK Announces Team-Wide Partnership with Esperion Therapeutics; Includes Primary Partnership for Brad Keselowski at the ’23 Daytona 500
2023-01-09 00:00 ET
Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results
2022-12-19 21:15 ET
CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology (ACC.23/WCC)
2022-12-13 23:00 ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2022-12-13 13:00 ET
Esperion to Participate in January Investor Meetings
2022-12-07 13:05 ET
Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint
2022-11-16 21:00 ET
Esperion Appoints Ben Halladay Chief Financial Officer
2022-11-09 13:00 ET
Esperion Virtual Research & Development Day to Highlight Pipeline Programs and Scientific Focus
2022-11-02 12:00 ET
Esperion to Participate in Jefferies London Healthcare Conference
2022-11-01 11:00 ET
Esperion Reports Third Quarter 2022 Financial Results and Provides Company Update
2022-10-27 12:00 ET
Esperion Hosting Virtual Research & Development Day
2022-10-19 20:00 ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2022-10-17 12:02 ET
Esperion to Report Third Quarter 2022 Financial Results November 1, 2022
2022-08-30 12:00 ET
Esperion to Participate in Upcoming September Investor Conferences
2022-08-26 12:16 ET
Esperion Announces Bempedoic Acid (NEXLETOL®) Recommended as Oral Non-Statin Therapy for LDL-Cholesterol Lowering in American College of Cardiology Expert Consensus Decision Pathway
2022-08-04 20:05 ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2022-08-02 11:00 ET
Esperion Reports Second Quarter 2022 Financial Results and Provides Company Update
2022-07-25 19:00 ET
Esperion Announces Establishment of Scientific Advisory Board to Support Pipeline and Life Cycle Management
2022-07-12 12:00 ET
Esperion to Report Second Quarter 2022 Financial Results August 2, 2022
2022-06-03 16:30 ET
Real World Data Analysis Reveals Nearly Half of All Adults at High Risk for ASCVD and Eligible for a Statin Were Not On Any Statin
2022-06-02 12:00 ET
Esperion to Participate in the 2022 Jefferies Global Healthcare Conference
2022-06-01 20:00 ET
Esperion Announces the Appointment of J. Martin Carroll to its Board of Directors
2022-05-31 12:00 ET
Esperion Announces Five Abstracts Accepted for Presentation at the National Lipid Association Scientific Sessions
2022-05-17 12:00 ET
Esperion to Participate in Upcoming H.C. Wainwright Global Investment Conference
2022-05-03 11:00 ET
Esperion Reports First Quarter 2022 Financial Results and Provides Company Update
2022-05-02 12:00 ET
Esperion Announces Publication of CLEAR Harmony Open-Label Extension Study Data for Bempedoic Acid in the American Journal of Cardiology
2022-04-29 21:00 ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2022-04-29 14:00 ET
Esperion to Participate in Upcoming Bank of America Securities 2022 Healthcare Conference
2022-04-28 20:00 ET
Esperion Announces the Appointment of Stephen Rocamboli to its Board of Directors
2022-04-25 12:00 ET
Esperion Supports Collaborative Study with an Integrated and Learning Health Care Delivery System in Northern California to Study the Effects of NEXLIZET® (bempedoic acid and ezetimibe) in Reducing LDL-Cholesterol Following a Recent Acute Coronary Syn...
2022-04-19 11:00 ET
Esperion to Report First Quarter 2022 Financial Results May 3, 2022
2022-04-13 12:00 ET
Esperion Announces Publication of Phase 3 Data for Bempedoic Acid in the Journal of Clinical Lipidology
2022-04-03 16:00 ET
Esperion Announces Two NEXLETOL® (bempedoic acid) Data Presentations at the American College of Cardiology’s 71st Annual Scientific Session & Expo
2022-03-29 12:00 ET
Esperion to Participate in Upcoming 21st Annual Needham Virtual Healthcare Conference
2022-02-24 13:00 ET
Esperion to Participate in Upcoming Virtual Cowen 42nd Annual Healthcare Conference
2022-02-22 12:00 ET
Esperion Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
2022-02-08 13:00 ET
Esperion to Report Fourth Quarter and Full Year 2021 Financial Results February 22, 2022
2022-01-28 22:00 ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2022-01-11 13:00 ET
Esperion Provides Preliminary Fourth Quarter 2021 Financial Results and CLEAR Outcomes Program Update
2022-01-06 13:00 ET
Esperion to Participate in Upcoming Virtual J.P. Morgan 40th Annual Healthcare Conference
2022-01-04 13:00 ET
Esperion Appoints Benjamin O. Looker as General Counsel
2021-12-07 21:05 ET
Esperion Announces Closing of $225 Million Public Offering
2021-12-03 04:40 ET
Esperion Announces Pricing of $225 Million Public Offering
2021-12-02 22:00 ET
Esperion Announces Proposed Public Offering
2021-11-12 12:00 ET
Esperion Presents Important New Science Highlighting Potential Benefits of NEXLETOL® (bempedoic acid) Tablets at American Heart Association Scientific Sessions 2021
2021-11-02 11:00 ET
Esperion Reports Third Quarter 2021 Financial Results and Provides Company Update
2021-11-01 20:01 ET
Esperion to Present Key Science at the American Heart Association Scientific Sessions 2021
2021-11-01 11:00 ET
Esperion Announces the Appointment of Seth H.Z. Fischer to its Board of Directors
2021-10-27 20:01 ET
Esperion to Participate in Upcoming Virtual Investor Conference
2021-10-25 11:00 ET
ESPERION Announces Agreement to Exchange $15 Million in Principal Amount of its 4.00% Convertible Senior Subordinated Notes due 2025 for Common Stock
2021-10-18 11:00 ET
ESPERION Announces Plan for Transformative Long-Term Growth
2021-10-12 12:00 ET
Esperion to Report Third Quarter 2021 Financial Results November 2, 2021
2021-09-07 20:01 ET
ESPERION to Host Investor Webinar on the Current Landscape and Future Directions in the Treatment of Elevated Cholesterol
2021-08-26 12:00 ET
Esperion to Participate in Upcoming Virtual Investor Conference
2021-08-03 11:00 ET
ESPERION Reports Second Quarter 2021 Financial Results and Provides Company Update
2021-07-27 12:00 ET
Esperion to Participate in Upcoming Virtual Investor Conference
2021-07-13 12:00 ET
Esperion to Report Second Quarter 2021 Financial Results August 3, 2021
2021-07-01 21:00 ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-06-28 11:59 ET
ESPERION Appoints JoAnne Micale Foody, MD, FACC, FAHA as Chief Medical Officer
2021-05-24 12:00 ET
Esperion to Participate in Two Upcoming Virtual Investor Conferences
2021-05-17 13:01 ET
ESPERION Appoints Sheldon Koenig as President and CEO
2021-05-15 16:00 ET
Simulation Model based on Pooled Phase 3 Data Demonstrating NEXLETOL® (bempedoic acid) Tablet’s Potential to Lower Absolute Cardiovascular Event Risk Presented at ACC.21
2021-05-06 12:00 ET
Esperion to Participate in Two Upcoming Virtual Investor Conferences
2021-05-04 20:01 ET
ESPERION Reports First Quarter 2021 Financial Results and Provides Company Update
2021-04-28 20:05 ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-04-27 12:00 ET
Esperion Announces Publication of Rationale and Design of Landmark CLEAR Cardiovascular Outcomes Trial Evaluating NEXLETOL® (bempedoic acid) Tablet in American Heart Journal
2021-04-26 20:07 ET
Esperion Secures $50 Million Funding from Oberland Capital
2021-04-26 20:02 ET
Esperion Expands Partnership with Daiichi Sankyo Group to Additional Territories
2021-04-12 20:01 ET
Esperion to Report First Quarter 2021 Financial Results May 4, 2021
2021-04-06 12:00 ET
Esperion to Participate in Fireside Chat at the 20th Annual Needham Virtual Healthcare Conference
2021-03-17 20:05 ET
NEXLETOL® (bempedoic acid) Tablet, ezetimibe and atorvastatin combination lowered bad cholesterol by 60.5% vs. placebo in Phase 2 study
2021-02-23 21:01 ET
ESPERION Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update
2021-02-09 13:00 ET
Esperion to Report Fourth Quarter and Full Year 2020 Financial Results February 23, 2021
2021-01-29 22:00 ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-01-13 11:26 ET
ESPERION Reports Preliminary Fourth Quarter 2020 Financial Results and Further Commits to Unmet Patient Needs with Oral PCSK9 Inhibitor Program
2020-12-21 13:00 ET
Esperion to Present at the 39th Annual J.P. Morgan Healthcare Conference
2020-12-16 08:00 ET
First-in-class cholesterol-lowering treatment NILEMDO® * (bempedoic acid) tablet and its combination with ezetimibe NUSTENDI® * (bempedoic acid and ezetimibe) tablet approved in Switzerland
2020-12-15 12:00 ET
ESPERION Appoints Sheldon Koenig as Chief Operating Officer
2020-11-13 14:15 ET
NEXLETOL® (bempedoic acid) Tablets Highlighted at AHA 2020 with Presentations of Analyses Demonstrating Significant Low-Density Lipoprotein Cholesterol (LDL-C) Lowering vs. Placebo in Phase 3 Study Subgroups
2020-11-12 11:17 ET
Esperion Announces Pricing of Offering of $250.0 Million of Convertible Senior Subordinated Notes
2020-11-10 21:30 ET
Esperion Announces Private Offering of $200.0 Million of Convertible Senior Subordinated Notes
2020-11-06 22:00 ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2020-11-02 21:01 ET
ESPERION Reports Third Quarter 2020 Financial Results and Provides Company Update
2020-10-27 12:00 ET
Esperion to Participate in Three Upcoming Virtual Investor Conferences
2020-10-19 12:00 ET
Esperion to Report Third Quarter 2020 Financial Results November 2, 2020
2020-10-07 12:00 ET
NEXLETOL® (bempedoic acid) Tablets Highlighted in EAS 2020 Presentation of Analysis Demonstrating Significant Cholesterol Lowering in People with Familial Hypercholesterolemia
2020-09-28 20:06 ET
Esperion Launches U.S. Direct-to-Consumer Campaign to Accelerate Awareness of NEXLETOL® (bempedoic acid) Tablets and Increase Awareness of Bad Cholesterol
2020-09-02 12:41 ET
Esperion to Participate in Two Upcoming Virtual Investor Conferences
2020-08-26 13:07 ET
Esperion Announces Two Data Presentations of NEXLETOL® (bempedoic acid) Tablet at the ESC Congress 2020
2020-08-21 20:05 ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2020-08-10 20:04 ET
Esperion Reports Second Quarter 2020 Financial Results and Provides Company Update
2020-08-03 11:26 ET
Esperion to Report Second Quarter 2020 Financial Results August 10, 2020
2020-07-01 15:12 ET
Esperion Announces Publication in the Journal of the American Medical Association Cardiology of Pooled Efficacy Analysis from the Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL® (bempedoic acid) Tablets
2020-06-22 11:00 ET
Esperion and Daiichi Sankyo Europe Announce Amendment to License and Commercial Collaboration Agreement
2020-06-14 13:30 ET
Esperion Announces Pooled Analysis from Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL™ (Bempedoic Acid) Tablets Presented at the American Diabetes Association 80th Scientific Sessions
2020-06-12 11:18 ET
Esperion Confirms NEXLETOL™ (bempedoic acid) Tablets to be Included in Assessment of Non-statin Medicines for Hypercholesterolemia by ICER
2020-06-08 12:00 ET
Esperion to Participate in Fireside Chat at the Goldman Sachs 41st Annual Global Healthcare Conference
2020-06-04 11:00 ET
Esperion Announces Commercial Availability of NEXLIZET™ (bempedoic acid and ezetimibe) Tablets and Ushers in New Era of Oral Combination Medicine for LDL-Cholesterol Lowering
2020-05-27 12:00 ET
Esperion to Participate in Fireside Chat at the Jefferies Virtual Global Healthcare Conference 2020
2020-05-15 22:00 ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2020-05-07 12:00 ET
Esperion to Participate in Fireside Chat at the BofA Securities 2020 Healthcare Conference
2020-05-06 20:05 ET
Esperion Reports First Quarter 2020 Financial Results and Provides Company Update
2020-04-30 12:00 ET
Esperion to Report First Quarter 2020 Financial Results May 6, 2020
2020-04-20 11:00 ET
Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL™ (bempedoic acid) and NEXLIZET™ (bempedoic acid and ezetimibe) Tablets in Japan
2020-04-09 12:00 ET
Esperion to Participate in Fireside Chat at the 19th Annual Needham Virtual Healthcare Conference
2020-04-06 11:05 ET
Esperion Announces European Commission Approval of the NUSTENDI™ (bempedoic acid and ezetimibe) Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
2020-04-06 11:00 ET
Esperion Announces European Commission Approval of the NILEMDO™ (bempedoic acid) Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
2020-03-30 20:15 ET
Esperion Announces Commercial Availability of the NEXLETOL™ (bempedoic acid) Tablet and Pledges a Conscientious Launch During Unprecedented Moment in Healthcare
2020-03-18 11:30 ET
Esperion Announces the Appointment of Alan Fuhrman to its Board of Directors
2020-02-28 21:15 ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2020-02-28 12:00 ET
Esperion to Participate in Upcoming Investor Conferences
2020-02-27 12:00 ET
Esperion Provides Lipid Management Franchise Updates; Reports Fourth Quarter and Full Year 2019 Financial Results
2020-02-26 22:30 ET
Esperion Announces FDA Approval of the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
2020-02-21 21:38 ET
Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
2020-01-31 12:02 ET
Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
2020-01-31 12:01 ET
Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for Bempedoic Acid for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
2020-01-07 12:30 ET
Esperion to Present at the 38th Annual J.P. Morgan Healthcare Conference
2020-01-03 21:15 ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2019-11-22 23:30 ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2019-11-17 20:05 ET
Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions
2019-11-12 16:05 ET
Esperion Announces Publication in the Journal of the American Medical Association of Bempedoic Acid Phase 3 Study 2 Results
2019-11-07 12:30 ET
Esperion to Participate in Upcoming Investor Conferences
2019-11-06 12:30 ET
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter Financial Results
2019-11-04 12:30 ET
Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of Bempedoic Acid to be Presented at the American Heart Association 2019 Scientific Sessions
2019-10-29 11:30 ET
Esperion to Report Third Quarter 2019 Financial Results November 6, 2019
2019-10-25 14:00 ET
Bempedoic Acid Included in Top 10 Medical Innovations for 2020 List
2019-04-24 18:12 ET
Moore Kuehn Encourages Esperion Therapeutics, Inc. Investors to Contact Law Firm for Possible Claims Against Officers and Directors
2019-04-02 20:30 ET
Esperion to Present at the Needham & Company 18th Annual Healthcare Conference
2019-04-02 09:10 ET
Bempedoic Acid CLEAR Serenity Study Results Published in the JAHA Demonstrated Significant LDL-Cholesterol Lowering and Reduced hsCRP in Statin Intolerant Patients
2019-04-01 20:15 ET
Esperion Announces Publication in The Journal of the American Heart Association of Bempedoic Acid Study 3 Results
2019-03-18 13:20 ET
Esperion Announces Late-Breaking Presentation of Final Results of Bempedoic Acid Pivotal Phase 3 Study 2 at the American College of Cardiology 2019 Scientific Sessions
2019-03-13 21:05 ET
Esperion Announces Publication of Bempedoic Acid Study 1 Results in The New England Journal of Medicine
2019-03-04 21:30 ET
Esperion to Participate in Upcoming Investor Conferences
2019-03-04 13:00 ET
Esperion Announces Presentation of Bempedoic Acid Pivotal Phase 3 Study 2 Results in a Late-Breaking Clinical Trial Session at the American College of Cardiology 2019 Scientific Sessions

SEC forms

Show financial reports only

SEC form 10
2024-05-07 08:50 ET
Esperion Therapeutics published news for 2024 q1
SEC form 8
2024-05-07 07:29 ET
Esperion Therapeutics published news for 2024 q1
SEC form 8
2024-05-07 07:29 ET
Esperion Therapeutics reported for 2024 q1
SEC form 10
2024-05-07 00:00 ET
Esperion Therapeutics published news for 2024 q1
SEC form 10
2024-02-27 09:19 ET
Esperion Therapeutics published news for 2023 q4
SEC form 8
2024-02-27 07:23 ET
Esperion Therapeutics published news for 2023 q4
SEC form 8
2024-02-27 07:23 ET
Esperion Therapeutics reported for 2023 q4
SEC form 10
2024-02-27 00:00 ET
Esperion Therapeutics published news for 2023 q4
SEC form 8
2024-01-11 00:00 ET
Esperion Therapeutics published news for 2023 q4
SEC form 8
2024-01-11 00:00 ET
Esperion Therapeutics published news for 2023 q4
SEC form 10
2023-11-07 08:52 ET
Esperion Therapeutics published news for 2023 q3
SEC form 8
2023-11-07 07:30 ET
Esperion Therapeutics reported for 2023 q3
SEC form 10
2023-11-07 00:00 ET
Esperion Therapeutics published news for 2023 q3
SEC form 10
2023-08-01 08:51 ET
Esperion Therapeutics reported for 2023 q2
SEC form 6
2023-08-01 07:07 ET
Esperion Therapeutics published news for 2023 q2
SEC form 10
2023-08-01 00:00 ET
Esperion Therapeutics published news for 2023 q2
SEC form 8
2023-08-01 00:00 ET
Esperion Therapeutics published news for 2023 q2
SEC form 6
2023-07-20 16:38 ET
Esperion Therapeutics published news for 2023 q2
SEC form 6
2023-06-26 06:03 ET
Esperion Therapeutics published news for 2023 q1
SEC form 6
2023-06-22 16:45 ET
Esperion Therapeutics published news for 2023 q1
SEC form 6
2023-06-16 16:09 ET
Esperion Therapeutics published news for 2023 q1
SEC form 6
2023-06-16 16:09 ET
Esperion Therapeutics published news for 2023 q1
SEC form 6
2023-06-16 16:08 ET
Esperion Therapeutics published news for 2023 q1
SEC form 6
2023-06-16 16:07 ET
Esperion Therapeutics published news for 2023 q1
SEC form 6
2023-06-16 16:06 ET
Esperion Therapeutics published news for 2023 q1
SEC form 6
2023-06-16 16:06 ET
Esperion Therapeutics published news for 2023 q1
SEC form 6
2023-06-16 16:05 ET
Esperion Therapeutics published news for 2023 q1
SEC form 6
2023-06-15 16:56 ET
Esperion Therapeutics published news for 2023 q1
SEC form 10
2023-05-09 00:00 ET
Esperion Therapeutics published news for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Esperion Therapeutics reported for 2023 q1
SEC form 6
2023-04-13 16:10 ET
Esperion Therapeutics published news for 2023 q1
SEC form 6
2023-04-03 16:13 ET
Esperion Therapeutics published news for 2023 q1
SEC form 6
2023-03-27 16:49 ET
Esperion Therapeutics published news for 2022 q4
SEC form 6
2023-03-22 16:40 ET
Esperion Therapeutics published news for 2022 q4
SEC form 6
2023-03-15 16:24 ET
Esperion Therapeutics published news for 2022 q4
SEC form 6
2023-03-15 09:21 ET
Esperion Therapeutics published news for 2022 q4
SEC form 6
2023-03-10 16:31 ET
Esperion Therapeutics published news for 2022 q4
SEC form 6
2023-03-06 06:04 ET
Esperion Therapeutics published news for 2022 q4
SEC form 10
2023-02-21 09:25 ET
Esperion Therapeutics reported for 2022 q4
SEC form 6
2023-02-21 07:30 ET
Esperion Therapeutics published news for 2022 q4
SEC form 10
2023-02-21 00:00 ET
Esperion Therapeutics reported for 2022 q4
SEC form 6
2023-01-09 09:04 ET
Esperion Therapeutics published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Esperion Therapeutics published news for 2022 q4
SEC form 6
2022-11-23 16:05 ET
Esperion Therapeutics published news for 2022 q3
SEC form 6
2022-11-16 16:11 ET
Esperion Therapeutics published news for 2022 q3
SEC form 6
2022-11-16 16:07 ET
Esperion Therapeutics published news for 2022 q3
SEC form 10
2022-11-01 08:52 ET
Esperion Therapeutics reported for 2022 q3
SEC form 6
2022-11-01 07:23 ET
Esperion Therapeutics published news for 2022 q3
SEC form 8
2022-11-01 00:00 ET
Esperion Therapeutics reported for 2022 q3
SEC form 10
2022-11-01 00:00 ET
Esperion Therapeutics reported for 2022 q3
SEC form 6
2022-09-20 16:40 ET
Esperion Therapeutics published news for 2022 q2
SEC form 6
2022-08-18 16:05 ET
Esperion Therapeutics published news for 2022 q2
SEC form 6
2022-08-08 16:02 ET
Esperion Therapeutics published news for 2022 q2
SEC form 10
2022-08-02 08:50 ET
Esperion Therapeutics published news for 2022 q2
SEC form 6
2022-08-02 07:24 ET
Esperion Therapeutics published news for 2022 q2
SEC form 10
2022-08-02 00:00 ET
Esperion Therapeutics reported for 2022 q2
SEC form 8
2022-08-02 00:00 ET
Esperion Therapeutics reported for 2022 q2
SEC form 6
2022-06-13 16:08 ET
Esperion Therapeutics published news for 2022 q1
SEC form 6
2022-06-03 16:11 ET
Esperion Therapeutics published news for 2022 q1
SEC form 6
2022-06-01 16:24 ET
Esperion Therapeutics published news for 2022 q1
SEC form 6
2022-06-01 16:20 ET
Esperion Therapeutics published news for 2022 q1
SEC form 6
2022-06-01 16:10 ET
Esperion Therapeutics published news for 2022 q1
SEC form 6
2022-05-27 16:20 ET
Esperion Therapeutics published news for 2022 q1
SEC form 6
2022-05-27 16:18 ET
Esperion Therapeutics published news for 2022 q1
SEC form 6
2022-05-27 16:17 ET
Esperion Therapeutics published news for 2022 q1
SEC form 6
2022-05-27 16:15 ET
Esperion Therapeutics published news for 2022 q1
SEC form 6
2022-05-27 16:14 ET
Esperion Therapeutics published news for 2022 q1
SEC form 6
2022-05-27 16:13 ET
Esperion Therapeutics published news for 2022 q1
SEC form 6
2022-05-27 16:12 ET
Esperion Therapeutics published news for 2022 q1
SEC form 6
2022-05-26 17:05 ET
Esperion Therapeutics published news for 2022 q1
SEC form 10
2022-05-03 08:57 ET
Esperion Therapeutics published news for 2022 q1
SEC form 6
2022-05-03 07:19 ET
Esperion Therapeutics published news for 2022 q1
SEC form 10
2022-05-03 00:00 ET
Esperion Therapeutics reported for 2022 q1
SEC form 8
2022-05-03 00:00 ET
Esperion Therapeutics reported for 2022 q1
SEC form 6
2022-04-28 16:37 ET
Esperion Therapeutics published news for 2022 q1
SEC form 6
2022-04-28 16:19 ET
Esperion Therapeutics published news for 2022 q1
SEC form 6
2022-04-14 16:03 ET
Esperion Therapeutics published news for 2022 q1
SEC form 6
2022-04-04 16:03 ET
Esperion Therapeutics published news for 2022 q1
SEC form 6
2022-03-15 16:00 ET
Esperion Therapeutics published news for 2021 q4
SEC form 6
2022-03-01 17:04 ET
Esperion Therapeutics published news for 2021 q4
SEC form 10
2022-02-22 09:03 ET
Esperion Therapeutics published news for 2021 q4
SEC form 6
2022-02-22 07:30 ET
Esperion Therapeutics published news for 2021 q4
SEC form 10
2022-02-22 00:00 ET
Esperion Therapeutics published news for 2021 q4
SEC form 8
2022-02-22 00:00 ET
Esperion Therapeutics published news for 2021 q4
SEC form 6
2022-01-11 08:24 ET
Esperion Therapeutics published news for 2021 q4
SEC form 8
2022-01-11 00:00 ET
Esperion Therapeutics published news for 2021 q4
SEC form 6
2022-01-04 08:28 ET
Esperion Therapeutics published news for 2021 q4
SEC form 6
2021-12-07 16:01 ET
Esperion Therapeutics published news for 2021 q3
SEC form 10
2021-11-02 09:03 ET
Esperion Therapeutics published news for 2021 q3
SEC form 6
2021-11-02 07:16 ET
Esperion Therapeutics published news for 2021 q3
SEC form 10
2021-11-02 00:00 ET
Esperion Therapeutics published news for 2021 q3
SEC form 8
2021-11-02 00:00 ET
Esperion Therapeutics published news for 2021 q3
SEC form 6
2021-11-01 16:30 ET
Esperion Therapeutics published news for 2021 q3
SEC form 6
2021-10-25 07:30 ET
Esperion Therapeutics published news for 2021 q3
SEC form 6
2021-10-18 07:30 ET
Esperion Therapeutics published news for 2021 q3
SEC form 8
2021-10-18 00:00 ET
Esperion Therapeutics published news for 2021 q3
SEC form 10
2021-08-03 08:56 ET
Esperion Therapeutics published news for 2021 q2
SEC form 6
2021-08-03 07:12 ET
Esperion Therapeutics published news for 2021 q2
SEC form 8
2021-08-03 00:00 ET
Esperion Therapeutics published news for 2021 q2
SEC form 10
2021-08-03 00:00 ET
Esperion Therapeutics published news for 2021 q2
SEC form 6
2021-06-28 16:03 ET
Esperion Therapeutics published news for 2021 q1
SEC form 6
2021-05-28 16:04 ET
Esperion Therapeutics published news for 2021 q1
SEC form 6
2021-05-17 09:09 ET
Esperion Therapeutics published news for 2021 q1
SEC form 10
2021-05-04 17:21 ET
Esperion Therapeutics published news for 2021 q1
SEC form 6
2021-05-04 16:10 ET
Esperion Therapeutics published news for 2021 q1
SEC form 10
2021-05-04 00:00 ET
Esperion Therapeutics published news for 2021 q1
SEC form 8
2021-05-04 00:00 ET
Esperion Therapeutics published news for 2021 q1
SEC form 6
2021-04-26 17:00 ET
Esperion Therapeutics published news for 2021 q1
SEC form 6
2021-04-15 16:02 ET
Esperion Therapeutics published news for 2021 q1
SEC form 10
2021-02-23 17:15 ET
Esperion Therapeutics published news for 2020 q4
SEC form 6
2021-02-23 16:15 ET
Esperion Therapeutics published news for 2020 q4
SEC form 6
2021-01-13 07:00 ET
Esperion Therapeutics published news for 2020 q4
SEC form 6
2020-12-16 07:36 ET
Esperion Therapeutics published news for 2020 q3
SEC form 6
2020-12-15 07:32 ET
Esperion Therapeutics published news for 2020 q3
SEC form 6
2020-11-16 17:15 ET
Esperion Therapeutics published news for 2020 q3
SEC form 6
2020-11-12 07:01 ET
Esperion Therapeutics published news for 2020 q3
SEC form 10
2020-11-02 17:21 ET
Esperion Therapeutics published news for 2020 q3
SEC form 6
2020-11-02 16:28 ET
Esperion Therapeutics published news for 2020 q3